FDA and HHS should im­prove in­sti­tu­tion­al re­view board in­spec­tion prac­tices, GAO says

The US Gov­ern­ment Ac­count­abil­i­ty Of­fice has made four rec­om­men­da­tions to the FDA and HHS to im­prove their over­sight of in­sti­tu­tion­al re­view boards’ (IRBs) own in­spec­tions of re­search stud­ies, ac­cord­ing to a new re­port.

IRBs are meant to keep a sharp eye on the ethics and safe­ty of re­search stud­ies in­volv­ing hu­man pa­tients, from be­hav­ioral stud­ies to clin­i­cal tri­als, in­clud­ing over­see­ing over­all con­duct and main­tain­ing da­ta in­tegri­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.